Business Wire

ADAPTIVEMOBILE-SECURITY

Share
AdaptiveMobile Security Uncovers Sophisticated Hacking Attacks on Mobile Phones, Exposing Massive Network Vulnerability

Following extensive research, AdaptiveMobile Security, a world leader in cyber-telecoms security, today announced it has uncovered a new and previously undetected vulnerability. This vulnerability is currently being exploited and is being used for targeted surveillance of mobile phone users. The vulnerability and its associated attacks have been named, ‘Simjacker’ as it involves the hijacking of SIM cards and threatens mobile phone users across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005038/en/

Simjacker extracts the location information of mobile phone users from vulnerable operators, retrieved using malicious SMS messages. The location information of thousands of devices was obtained over time without the knowledge or consent of the targeted mobile phone users. Based on previous intelligence, it is likely that these attacks originated from a surveillance company which works with governments, to track and monitor individuals; bypassing existing signalling protection.

Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security explained, “Simjacker represents a clear danger to the mobile operators and subscribers. This is potentially the most sophisticated attack ever seen over core mobile networks. It’s a major wake-up call that shows hostile actors are investing heavily in increasingly complex and creative ways to undermine network security. This compromises the security and trust of customers, mobile operators and impacts the national security of entire countries.”

While the primary attack detected involved the retrieval of mobile phone locations, Simjacker has been further exploited to perform many other types of attacks against individuals and mobile operators such as fraud, scam calls, information leakage, denial of service and espionage. AdaptiveMobile Security Threat Intelligence analysts observed the hackers vary their attacks, testing many of these further exploits.

In theory, all makes and models of mobile phone are open to attack as the vulnerability is linked to a technology embedded on SIM cards. AdaptiveMobile Security research indicates that the Simjacker vulnerability could extend to over 1 billion mobile phone users globally, potentially impacting countries in North and South America, West Africa, Europe, Middle East and indeed any region of the world where this SIM card technology is in use.

Mc Daid continued, “Simjacker worked so well and was being successfully exploited for years because it took advantage of a combination of complex interfaces and obscure technologies, showing that mobile operators cannot rely on standard established defences. Now that this vulnerability has been revealed, we fully expect the exploit authors and other malicious actors will try to evolve these attacks into other areas”.

AdaptiveMobile Security has been working closely with their customers and the wider industry; including both mobile network operators and SIM card manufacturers to protect mobile phone subscribers. AdaptiveMobile Security are committed to using their global threat intelligence to build defences against these new sophisticated attacks that are circumventing current security measures.

Further details on Simjacker are available on www.simjacker.com and Cathal Mc Daid, Chief Technology Officer of AdaptiveMobile Security will be presenting on Simjacker at the Virus Bulletin Conference, London, 3 October 2019.

---Ends---

About

AdaptiveMobile Security is the world leader in cyber-telecoms security, protecting over 2.1 billion subscribers worldwide. The combination of global insight provided by our security specialists teams, our world-leading Threat Intelligence Unit and our proprietary, telecom-grade Network Protection Platform are trusted by the world’s largest service providers to secure their critical communications infrastructure.

The Company HQ is in Dublin with offices in North America, Europe, South Africa, the Middle East and Asia Pacific.

www.adaptivemobile.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye